Biological Unicorn: DeepMind Spin-Off Isomorphic Labs in Funding Talks at $50B Valuation

The operational intersection of artificial intelligence and biopharmaceuticals has evolved into one of the global economy’s most capital-intensive verticals. On October 8, 2026, Bloomberg revealed that Isomorphic Labs—the drug discovery enterprise spun out from Google DeepMind leveraging AlphaFold architectures—is in early-stage talks to raise new capital targeting a valuation between $40 billion and $50 billion.

Coming roughly five months after securing a $2.1 billion Series B facility, the potential valuation reset demonstrates surging investor conviction surrounding applied AI for Science. Institutional allocators view algorithmic protein folding, target identification, and de novo molecule design as superior value-creation engines relative to general-purpose LLMs, positioning computational drug discovery as the successor to traditional pharmaceutical research pipelines.

Source: Bloomberg / Yahoo Finance